ACOG
Alpha Cognition Inc. Common StockACOG
ACOG
About: Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.
Employees: 57
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
1.3% more ownership
Funds ownership: 38.27% [Q4 2024] → 39.57% (+1.3%) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]
4% less funds holding
Funds holding: 23 [Q4 2024] → 22 (-1) [Q1 2025]
7% less capital invested
Capital invested by funds: $34.9M [Q4 2024] → $32.4M (-$2.46M) [Q1 2025]
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$20
114%
upside
Avg. target
$20
114%
upside
High target
$20
114%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Raghuram Selvaraju | 114%upside $20 | Buy Reiterated | 16 May 2025 |
Financial journalist opinion
Neutral
Seeking Alpha
3 weeks ago
Alpha Cognition: Launching A Differentiated Drug Into A Large Alzheimer's Market Opportunity
Zunveyl nearly eliminates the onerous GI and sleep disturbance side effects of gold-standard AChEI drugs used to treat Alzheimer's. With failure of anti-amyloid antibodies and no clear disease-modifying therapies in late-stage development (yet), the $5.5 billion Alzheimer's market is severely underserved and dissatisfied. Lean, experienced commercial team launched Zunveyl in March into the long-term care (LTC) market vertical, which accounts for 32% of Alzheimer's scripts.
Neutral
Newsfile Corp
3 weeks ago
Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q1 2025
Dallas, Texas--(Newsfile Corp. - May 19, 2025) - Alpha Cognition Inc. (NASDAQ: ACOG): Stonegate Capital Partners updates their coverage on Alpha Cognition Inc. (NASDAQ: ACOG). Alpha Cognition began 2025 by launching ZUNVEYL(R) (benzgalantamine) to the U.S. long-term care (LTC) market on March 17, 2025, delivering on its commercialization timeline and budget.
Neutral
Seeking Alpha
1 month ago
Alpha Cognition Inc. (ACOG) Q1 2025 Earnings Call Transcript
Alpha Cognition Inc. (NASDAQ:ACOG ) Q1 2025 Earnings Conference Call May 15, 2025 4:30 PM ET Company Participants Henry Du - Interim CFO Michael McFadden - CEO Lauren D'Angelo - COO Conference Call Participants Ram Selvaraju - H.C. Wainwright Michael Freeman - Raymond James Dave Storms - Stonegate Operator Greetings and welcome to the Alpha Cognition earnings call.
Negative
Zacks Investment Research
1 month ago
Alpha Cognition Inc. (ACOG) Reports Q1 Loss, Misses Revenue Estimates
Alpha Cognition Inc. (ACOG) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.58. This compares to loss of $0.75 per share a year ago.
Neutral
Business Wire
1 month ago
Alpha Cognition Inc. Reports First Quarter 2025 Financial Results and Operating Overview
VANCOUVER, British Columbia--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”) today announced its financial results for the first quarter ended March 31, 2025. “We closed the quarter on a strong note, launching ZUNVEYL® to the long-term care market,” said Michael McFadden, Chief Executive Officer. “We feel that the company is operating at a high level and are on schedule and within budget on all of our launch plans. Early market feedback on ZUNVEYL util.
Neutral
Business Wire
1 month ago
Alpha Cognition to Report First Quarter 2025 Financial Results and Operating Overview
VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today will announce financial results for the first quarter ended March 31, 2025 on May 15, 2025 after close of market. Following the release, management will host a conference call to review financial and operating results. Conference Call Information: To participate in the conference call, please use the dial-.
Neutral
Newsfile Corp
1 month ago
Alpha Cognition, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference
Grapevine, Texas--(Newsfile Corp. - April 30, 2025) - Alpha Cognition, Inc. (NASDAQ: ACOG), today announced its participation in the D. Boral Capital Inaugural Global Conference, taking place May 14, 2025, at The Plaza Hotel in New York City.
Neutral
Business Wire
1 month ago
Alpha Cognition to Present ZUNVEYL® (Benzgalantamine) Clinical Data at 2025 Alzheimer's Association International Conference
VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) (the “Company” or “Alpha Cognition”) today announced three upcoming presentations at the 2025 Alzheimer's Association International Conference (the “AAIC”), taking place July 27–31, 2025 in Toronto, Canada. The presentations will highlight clinical studies supporting ZUNVEYL (benzgalantamine), the Company's lead product and a novel galantamine prodrug approved by the FDA in July 2024 and commercially laun.
Neutral
Business Wire
2 months ago
Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens
VANCOUVER & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Robert Wills, Ph.D., to its Board of Directors, effective immediately April 7, 2025. Dr. Wills brings decades of experience in the pharmaceutical and biotechnology industries, with a distinguished career in drug development, corporate str.
Neutral
Newsfile Corp
2 months ago
Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q4 2024
Dallas, Texas--(Newsfile Corp. - April 1, 2025) - Alpha Cognition Inc. (NASDAQ: ACOG): Stonegate Capital Partners updates their coverage on Alpha Cognition Inc. (NASDAQ: ACOG). Alpha Cognition had a strong 2024 after raising $52.8M and uplisting to NASDAQ, significantly enhancing its capital base and market visibility.
Charts implemented using Lightweight Charts™